Trump contradicts stance on healthcare for patients with pre-existing conditions

President Trump tweeted Oct. 18 that all Republicans support patients with pre-existing conditions, “and if they don’t, they will after I speak to them”—a sentiment that directly contradicts the Trump administration’s efforts to strip the Affordable Care Act of its protections for such patients.

“I am in total support,” Trump continued, though he’s publicly supported repeal bills in the House and Senate that would grant individual states the authority to allow insurers to spike premiums for those with pre-existing conditions. 

The Trump administration announced this June it would no longer support the ACA’s protections for people with pre-existing conditions in an ongoing lawsuit launched by Republicans, arguing the measures were unconstitutional and should be deemed invalid.

And though Republicans “have been scrambling to show that they do support the protections,” the Hill reported, they’ve argued recently that Democratic efforts to implement Medicare for all would pile unsustainable costs on the program. Democrats, on the other hand, argue the policy would expand benefits for patients who need them most.

“I will always fight for and always protect patients with pre-existing conditions,” Trump said at a rally in West Virginia this fall, negating earlier reports. “We’ll do it the right way, too. Pre-existing conditions are safe, OK? Just remember that.”

Read more at the link below:

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.